Advertising
Agriculture
Airlines-Aviation
Aerospace-Defense
Art
Auto
Banking-Financial Services
Beer, Wine & Spirits
Biometrics
Biotechnology
Books
Charity
Chemical
Computer Electronics
Computer Gaming
Computer Hardware
Computer Networks
Computer Software
Construction-Building
Consumer Electronics
Death Care Services
Education
Electronic Commerce
Electronic Components
Electronic Design Automation
Electronics Performance Measurement
Entertainment
Environmental Services
Fashion
Film-Motion-Picture
Food-Beverages
Gambling-Casinos
Government
Health Care-Hospitals
High-Tech Security
Higher Education
Homeland Security
Household-Consumer-Cosmetics
Infectious Disease Control
Insurance
Internet Technology
Legal
Leisure-Travel-Hotels
Machinery
Magazines
Maritime-Shipbuilding
Medical-Pharmaceuticals
Mining-Metals
Mobile Entertainment
Multimedia-Online-Internet
Music
Mutual Funds
Nanotechnology
Office Products
Oil-Energy
Otc-Smallcap
Paper-Forest-Products-Containers
Peripherals
Publishing-Information Services
Radio
Real Estate
Religion
Restaurants
Retail
Safety
Semiconductors
Sports
Supermarkets
Supplementary Medicine
Telecommunications
Television
Temporary Staffing Services
Textiles
Tobacco
Transportation-Trucking-Railroad
Travel
Utilities
Workforce Management/Human Resources
News Releases For June 7, 2009

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs

New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

More Than 80 Celebrities to Come Together at the 20th Anniversary A Time for Heroes Celebrity Carnival Sponsored by Disney to Benefit the Elizabeth Glaser Pediatric AIDS Foundation

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

New Pooled Analysis Found Lantus(R) Reduced A1C and FBG Levels in Adults Over 65 with Type 2 Diabetes Compared to Those Treated with NPH

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

Reata Presents Promising Data on Bardoxolone at American Diabetes Association Annual Scientific Meeting

Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2009 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.